MACH4 Pharma Systems Receives German Global Health Award for South Africa Pharmacy Access Initiative

MOUNTAIN VIEW, Calif., June 8, 2017 /PRNewswire/ -- Omnicell, Inc. (NASDAQ: OMCL) today announced that its robotic dispensing solutions company, MACH4 Automatisierungstechnik GmbH, has been recognized by the German Healthcare Partnership, the Federation of German Industries, and the Biotechnology Industry Organization of Germany for its efforts in innovation to provide better access to pharmacy services in South Africa. The Federal Minister of Economics and Energy, Brigitte Zypries, presented the Company with the German Global Health award at the Allianz Forum, Pariser Platz in Berlin, on May 17.

MACH4 Automatisierungstechnik GmbH was recognized for its Pharmacy of the Future project. Pharmacy of the Future places robotic dispensing systems, with Patient Dispensing Units (PDUs), in shopping centers to improve access to medicines in South Africa. The program was developed in partnership with Right to Care, Right ePharmacy, the Department of Health South Africa, The Deutsche Gesellschaft für International Zusammenarbeit GmbH and USAID. Goals of the project are easier accessibility and decreased waiting times in outpatient pharmacies for patients with stable but chronic conditions. Patients without access to these systems have to travel to clinics and hospitals every month to refill their prescriptions, even if they are stable and do not require medical consultation. Waiting times for these patients can average four to five hours.

The collaboration seeks to provide better access and adherence to medications for the estimated 7.5 million South Africans infected with human immunodeficiency virus (HIV). The partnership began as a pilot project that will be handed to the national health system to ensure sustainability and structural adaptability going forward.

"We're honored to be recognized with the German Global Health award," said Dirk Beils, senior director, Engineering at MACH4 Automatisierungstechnik GmbH. "Just as we're inspired by the care providers deliver in the acute setting, we're also committed to creating a better life for those who are actively advocating for their own health. We hope the implementation of these PDUs will forge a pathway toward a healthier population that will continue to serve the country of South Africa for years to come."

About Omnicell

Since 1992, Omnicell (NASDAQ: OMCL) has been inspired to create safer and more efficient ways to manage medications and supplies across all care settings. As a leader in medication and supply dispensing automation, central pharmacy automation, IV robotics, analytics software, and medication adherence and packaging systems, Omnicell is focused on improving care across the entire healthcare continuum—from the acute care hospital setting, to post-acute skilled nursing and long-term care facilities, to the patient's home.

Over 4,000 customers worldwide use Omnicell^® automation and analytics solutions to increase operational efficiency, reduce medication errors, deliver actionable intelligence and improve patient safety.

Omnicell's innovative medication adherence solutions, used by over 32,000 institutional and retail pharmacies in North America and the United Kingdom, are designed to improve patient adherence to prescriptions, helping to reduce costly hospital readmissions.

Recent Omnicell acquisitions, including Ateb, add distinct capabilities, particularly in central pharmacy, IV robotics, and pharmacy software, creating the broadest medication management product portfolio in the industry.

For more information about Omnicell, Inc. please visit www.omnicell.com.

OMCL-G

Editor's Notes:

1. All Omnicell news releases (financial, acquisitions, products, technology etc.) are issued exclusively by PR Newswire and are immediately thereafter posted on the company's external website, omnicell.com.
2. Omnicell and the Omnicell logo design are registered trademarks of Omnicell, Inc.
3. All other brand or product names may be trademarks or registered trademarks of their respective companies.

SOURCE Omnicell, Inc.

Related Links

http://www.omnicell.com